Additional File 6 of Model Based on Five Tumour Immune Microenvironment-Related Genes for Predicting Hepatocellular Carcinoma Immunotherapy Outcomes

Xinyu Gu,Jun Guan,Jianhua Xu,Qiuxian Zheng,Chao Chen,Qidong Yang,ChunHong Huang,Gang Wang,Haibo Zhou,Zhi Chen,Haihong Zhu

DOI: https://doi.org/10.6084/m9.figshare.13531699

2021-01-01

Abstract:Additional file 6. Additional material.

What problem does this paper attempt to address?

Based on Tumor Mutation Burden to construct diagnosis and prognosis models and provides guidance for the treatment in the Hepatocellular Carcinoma patients

Bufu Tang,Jinyu Zhu,Zhongwei Zhao,Chenying Lu,Siyu Liu,Shiji Fang,Liyun Zheng,Nannan Zhang,Minjiang Chen,Min Xu,Risheng Yu,Jiansong Ji

DOI: https://doi.org/10.1016/J.JARE.2021.01.018

IF: 12.822

2021-01-01

Journal of Advanced Research

Abstract:Abstract Introduction The development and prognosis of HCC involve complex molecular mechanisms, which affect the effectiveness of its treatment strategies. Tumor mutational burden (TMB) is related to the efficacy of immunotherapy, but the prognostic role of TMB-related genes in HCC has not yet been determined clearly. Objectives In this study, we identified TMB-specific genes with good prognostic value to build diagnostic and prognostic models and provide guidance for the treatment of HCC patients. Methods Weighted gene co-expression network analysis (WGCNA) was applied to identify the TMB-specific genes. And LASSO method and Cox regression were used in establishing the prognostic model. Results The prognostic model based on SMG5 and MRPL9 showed patients with higher prognostic risk had a remarkedly poorer survival probability than their counterparts with lower prognostic risk in both a TCGA cohort (P Conclusion Our study helps to select patients suitable for chemotherapy, targeted drugs and immunotherapy and provide new ideas for developing treatment strategies to improve disease outcomes in HCC patients.
Diagnosis and prognosis models for hepatocellular carcinoma patient's management based on tumor mutation burden

Bufu Tang,Jinyu Zhu,Zhongwei Zhao,Chenying Lu,Siyu Liu,Shiji Fang,Liyun Zheng,Nannan Zhang,Minjiang Chen,Min Xu,Risheng Yu,Jiansong Ji

DOI: https://doi.org/10.1016/j.jare.2021.01.018

IF: 12.822

2021-01-01

Journal of Advanced Research

Abstract:Introduction: The development and prognosis of HCC involve complex molecular mechanisms, which affect the effectiveness of its treatment strategies. Tumor mutational burden (TMB) is related to the efficacy of immunotherapy, but the prognostic role of TMB-related genes in HCC has not yet been determined clearly. Objectives: In this study, we identified TMB-specific genes with good prognostic value to build diagnostic and prognostic models and provide guidance for the treatment of HCC patients. Methods: Weighted gene co-expression network analysis (WGCNA) was applied to identify the TMB-specific genes. And LASSO method and Cox regression were used in establishing the prognostic model. Results: The prognostic model based on SMG5 and MRPL9 showed patients with higher prognostic risk had a remarkedly poorer survival probability than their counterparts with lower prognostic risk in both a TCGA cohort (P < 0.001, HR = 1.93) and an ICGC cohort (P < 0.001, HR = 3.58). In addition, higher infiltrating fractions of memory B cells, M0 macrophages, neutrophils, activated memory CD4 + T cells, follicular helper T cells and regulatory T cells and higher expression of B7H3, CTLA4, PD1, and TIM3 were present in the high-risk group than in the low-risk group (P < 0.05). Patients with high prognostic risk had higher resistance to some chemotherapy and targeted drugs, such as methotrexate, vinblastine and erlotinib, than those with low prognostic risk (P < 0.05). And a diagnostic model considering two genes was able to accurately distinguish patients with HCC from normal samples and those with dysplastic nodules. In addition, knockdown of SMG5 and MRPL9 was determined to significantly inhibit cell proliferation and migration in HCC. Conclusion: Our study helps to select patients suitable for chemotherapy, targeted drugs and immunotherapy and provide new ideas for developing treatment strategies to improve disease outcomes in HCC patients. (C) 2021 The Authors. Published by Elsevier B.V. on behalf of Cairo University.
Model based on five tumour immune microenvironment-related genes for predicting hepatocellular carcinoma immunotherapy outcomes

Xinyu Gu,Jun Guan,Jia Xu,Qiuxian Zheng,Chao Chen,Qin Yang,Chunhong Huang,Gang Wang,Haibo Zhou,Zhi Chen,Haihong Zhu

DOI: https://doi.org/10.1186/s12967-020-02691-4

IF: 8.44

2021-01-06

Journal of Translational Medicine

Abstract:Abstract Background Although the tumour immune microenvironment is known to significantly influence immunotherapy outcomes, its association with changes in gene expression patterns in hepatocellular carcinoma (HCC) during immunotherapy and its effect on prognosis have not been clarified. Methods A total of 365 HCC samples from The Cancer Genome Atlas liver hepatocellular carcinoma (TCGA-LIHC) dataset were stratified into training datasets and verification datasets. In the training datasets, immune-related genes were analysed through univariate Cox regression analyses and least absolute shrinkage and selection operator (LASSO)-Cox analyses to build a prognostic model. The TCGA-LIHC, GSE14520, and Imvigor210 cohorts were subjected to time-dependent receiver operating characteristic (ROC) and Kaplan–Meier survival curve analyses to verify the reliability of the developed model. Finally, single-sample gene set enrichment analysis (ssGSEA) was used to study the underlying molecular mechanisms. Results Five immune-related genes ( LDHA , PPAT , BFSP1 , NR0B1, and PFKFB4 ) were identified and used to establish the prognostic model for patient response to HCC treatment. ROC curve analysis of the TCGA (training and validation sets) and GSE14520 cohorts confirmed the predictive ability of the five-gene-based model (AUC > 0.6). In addition, ROC and Kaplan–Meier analyses indicated that the model could stratify patients into a low-risk and a high-risk group, wherein the high-risk group exhibited worse prognosis and was less sensitive to immunotherapy than the low-risk group. Functional enrichment analysis predicted potential associations of the five genes with several metabolic processes and oncological signatures. Conclusions We established a novel five-gene-based prognostic model based on the tumour immune microenvironment that can predict immunotherapy efficacy in HCC patients.

medicine, research & experimental
Comprehensive Study of Tumor Immune Microenvironment and Relevant Genes in Hepatocellular Carcinoma Identifies Potential Prognostic Significance

Wenbiao Chen,Xujun Zhang,Kefan Bi,Hetong Zhou,Jia Xu,Yong Dai,Hongyan Diao

DOI: https://doi.org/10.3389/fonc.2020.554165

IF: 4.7

2020-01-01

Frontiers in Oncology

Abstract:Background:The tumor immune microenvironment (TIME) is an external immune system that regulates tumorigenesis. However, cellular interactions involving the TIME in hepatocellular carcinoma (HCC) are poorly characterized. Methods:In this study, we used multidimensional bioinformatic methods to comprehensively analyze cellular TIME characteristics in 735 HCC patients. Additionally, we explored associations involving TIME molecular subtypes and gene types and clinicopathological features to construct a prognostic signature. Results:Based on their characteristics, we classified TIME and gene signatures into three phenotypes (TIME T1-3) and two gene clusters (Gene G1-2), respectively. Further analysis revealed that Gene G1 was associated with immune activation and surveillance and included CD8(+)T cells, natural killer cell activation, and activated CD4(+)memory T cells. In contrast, Gene G2 was characterized by increased M0 macrophage and regulatory T cell levels. After calculation of principal component algorithms, a TIME score (TS) model, including 78 differentially expressed genes, was constructed based on TIME phenotypes and gene clusters. Furthermore, we observed that the Gene G2 cluster was characterized by high TS, and Gene G1 was characterized by low TS, which correlated with poor and favorable prognosis of HCC, respectively. Correlation analysis showed that TS had a positive association with several clinicopathologic signatures[such as grade, stage, tumor (T), and node (N)] and known somatic gene mutations (such asTP53andCTNNB1). The prognostic value of the TS model was verified using external data sets. Conclusion:We constructed a TS model based on differentially expressed genes and involving immune phenotypes and demonstrated that the TS model is an effective prognostic biomarker and predictor for HCC patients.
Immune Classifier-Based Signatures Provide Good Prognostic Stratification and Predict the Clinical Benefits of Immune-Based Therapies for Hepatocellular Carcinoma

Xue Chen,Gu Xinyu,Li Lanjuan

DOI: https://doi.org/10.1186/s12935-021-02183-5

IF: 6.429

2021-01-01

Cancer Cell International

Abstract:Background Hepatocellular carcinoma (HCC) is an aggressive cancer with a high rate of death globally. The use of bioinformatics may help to identify immune cell-related genes both as targets for potential immunotherapies and for their value associated with predicting therapy responses. Methods In this study, mRNA expression profiles of HCC samples from The Cancer Genome Atlas (TCGA) database were subjected to gene enrichment, cell type abundance, immune cell infiltration, and pathway enrichment analyses to determine immune cell gene features, cell type abundance, and functional annotation characteristics. We also evaluated their prognostic values using Cox regression and Kaplan–Meier analyses and assessed potential responses to chemotherapy. Four subgroups (Groups 1–4) were identified. Group 4 was associated with advanced clinical characteristics, high immune cell enrichment scores, and the poorest outcomes. Results Differentially expressed genes (DEGs) in the HCC samples were enriched in the following pathways: antigen binding, cell surface receptor signal transduction of the immune response, and cell surface activated receptor signal transduction of the immune response. Highly expressed genes in Group 4 were enriched in elements of the WNT signalling pathway. We identified five immune-related genes ( SEMA3A, TNFRSF11B, GUCA2A, SAA1 , and CALCR ) that were significantly related to HCC prognosis. A prognostic model based on these five genes exhibited good predictive value, with 1-year and 5-year area under the curve (AUC) values of > 0.66. Group 4 was also potentially more sensitive to EHT 1864, FH535, and lapatinib chemotherapies than the other groups. Conclusions We identified and validated four HCC subgroups based on immune system-related genes and identified five genes that may be used for an immune-based prognostic model for HCC treatment.
Systematic Construction and Validation of a Prognostic Model for Hepatocellular Carcinoma Based on Immune-Related Genes

Jiahao Yu,Shuoyi Ma,Siyuan Tian,Miao Zhang,Xiaopeng Ding,Yansheng Liu,Fangfang Yang,Yinan Hu,Guoyun Xuan,Xinmin Zhou,Jingbo Wang,Ying Han

DOI: https://doi.org/10.3389/fcell.2021.700553

IF: 5.5

2021-10-04

Frontiers in Cell and Developmental Biology

Abstract:Hepatocellular carcinoma (HCC), a highly aggressive tumor, has high incidence and mortality rates. Recently, immunotherapies have been shown to be a promising treatment in HCC. The results of either the CheckMate-040 or IMbrave 150 trials demonstrate the importance of immunotherapy in the systemic treatment of liver cancer. Thus, in this study, we tried to establish a reliable prognostic model for liver cancer based on immune-related genes (IRGs) and to provide a new insight for immunotherapy of HCC. In this study, we used four datasets that incorporated 851 HCC samples, including 340 samples with complete clinical information from the cancer genome atlas (TCGA) database, to establish an effective model for predicting the prognosis of HCC patients based on the differential expression of IRGs and validated the prognostic model using the data from International Cancer Genome Consortium (ICGC). The top 6 characteristic IRGs identified by protein-protein interaction (PPI) network analysis, MMP9, FOS, CAT, ESR1, ANGPTL3, and KLKB1, were selected for further study. In addition, we assessed the correlations of the six characteristic IRGs with the tumor immune microenvironment, clinical stage, and sensitivity to anti-cancer drugs. We also explored whether the differential expression of the characteristic IRGs was specific to HCC or present in pan-cancer. The expression levels of the six characteristic IRGs were significantly different between most tumor tissues and adjacent normal tissues. In addition, these characteristic IRGs showed a strong association with immune cell infiltration in HCC patients. We found that MMP9 and ESR1 were independent prognostic factors for HCC, while CAT, ESR1, and KLKB1 were associated with the clinical stage. We collected HCC paraffin sections from 24 patients from Xijing hospital to identify the differential expression of the five genes (MMP9, ESR1, CAT, FOS, and KLKB1). Finally, the results of decision curve analysis (DCA) and nomogram revealed that our models provided a prognostic benefit for most HCC patients and the predicted overall survival (OS) was consistent with the actual OS. In conclusion, we systemically constructed a novel prognostic model that provides new insights into HCC.

cell biology,developmental biology
Identification and validation of immune-related gene signature models for predicting prognosis and immunotherapy response in hepatocellular carcinoma

Zhiqiang Liu,Lingge Yang,Chun Liu,Zicheng Wang,Wendi Xu,Jueliang Lu,Chunmeng Wang,Xundi Xu

DOI: https://doi.org/10.3389/fimmu.2024.1371829

IF: 7.3

2024-06-13

Frontiers in Immunology

Abstract:Background: This study seeks to enhance the accuracy and efficiency of clinical diagnosis and therapeutic decision-making in hepatocellular carcinoma (HCC), as well as to optimize the assessment of immunotherapy response. Methods: A training set comprising 305 HCC cases was obtained from The Cancer Genome Atlas (TCGA) database. Initially, a screening process was undertaken to identify prognostically significant immune-related genes (IRGs), followed by the application of logistic regression and least absolute shrinkage and selection operator (LASSO) regression methods for gene modeling. Subsequently, the final model was constructed using support vector machines-recursive feature elimination (SVM-RFE). Following model evaluation, quantitative polymerase chain reaction (qPCR) was employed to examine the gene expression profiles in tissue samples obtained from our cohort of 54 patients with HCC and an independent cohort of 231 patients, and the prognostic relevance of the model was substantiated. Thereafter, the association of the model with the immune responses was examined, and its predictive value regarding the efficacy of immunotherapy was corroborated through studies involving three cohorts undergoing immunotherapy. Finally, the study uncovered the potential mechanism by which the model contributed to prognosticating HCC outcomes and assessing immunotherapy effectiveness. Results: SVM-RFE modeling was applied to develop an OS prognostic model based on six IRGs (CMTM7, HDAC1, HRAS, PSMD1, RAET1E, and TXLNA). The performance of the model was assessed by AUC values on the ROC curves, resulting in values of 0.83, 0.73, and 0.75 for the predictions at 1, 3, and 5 years, respectively. A marked difference in OS outcomes was noted when comparing the high-risk group (HRG) with the low-risk group (LRG), as demonstrated in both the initial training set ( P < 0.0001) and the subsequent validation cohort ( P < 0.0001). Additionally, the SVMRS in the HRG demonstrated a notable positive correlation with key immune checkpoint genes (CTLA-4, PD-1, and PD-L1). The results obtained from the examination of three cohorts undergoing immunotherapy affirmed the potential capability of this model in predicting immunotherapy effectiveness. Conclusions: The HCC predictive model developed in this study, comprising six genes, demonstrates a robust capability to predict the OS of patients with HCC and immunotherapy effectiveness in tumor management.

immunology
A Prognostic Model Based on Seven Immune-Related Genes Predicts the Overall Survival of Patients with Hepatocellular Carcinoma

Qian Yan,Wenjiang Zheng,Boqing Wang,Baoqian Ye,Huiyan Luo,Xinqian Yang,Ping Zhang,Xiongwen Wang

DOI: https://doi.org/10.1186/s13040-021-00261-y

2021-01-01

BioData Mining

Abstract:BACKGROUND:Hepatocellular carcinoma (HCC) is a disease with a high incidence and a poor prognosis. Growing amounts of evidence have shown that the immune system plays a critical role in the biological processes of HCC such as progression, recurrence, and metastasis, and some have discussed using it as a weapon against a variety of cancers. However, the impact of immune-related genes (IRGs) on the prognosis of HCC remains unclear.METHODS:Based on The Cancer Gene Atlas (TCGA) and Immunology Database and Analysis Portal (ImmPort) datasets, we integrated the ribonucleic acid (RNA) sequencing profiles of 424 HCC patients with IRGs to calculate immune-related differentially expressed genes (DEGs). Survival analysis was used to establish a prognostic model of survival- and immune-related DEGs. Based on genomic and clinicopathological data, we constructed a nomogram to predict the prognosis of HCC patients. Gene set enrichment analysis further clarified the signalling pathways of the high-risk and low-risk groups constructed based on the IRGs in HCC. Next, we evaluated the correlation between the risk score and the infiltration of immune cells, and finally, we validated the prognostic performance of this model in the GSE14520 dataset.RESULTS:A total of 100 immune-related DEGs were significantly associated with the clinical outcomes of patients with HCC. We performed univariate and multivariate least absolute shrinkage and selection operator (Lasso) regression analyses on these genes to construct a prognostic model of seven IRGs (Fatty Acid Binding Protein 6 (FABP6), Microtubule-Associated Protein Tau (MAPT), Baculoviral IAP Repeat Containing 5 (BIRC5), Plexin-A1 (PLXNA1), Secreted Phosphoprotein 1 (SPP1), Stanniocalcin 2 (STC2) and Chondroitin Sulfate Proteoglycan 5 (CSPG5)), which showed better prognostic performance than the tumour/node/metastasis (TNM) staging system. Moreover, we constructed a regulatory network related to transcription factors (TFs) that further unravelled the regulatory mechanisms of these genes. According to the median value of the risk score, the entire TCGA cohort was divided into high-risk and low-risk groups, and the low-risk group had a better overall survival (OS) rate. To predict the OS rate of HCC, we established a gene- and clinical factor-related nomogram. The receiver operating characteristic (ROC) curve, concordance index (C-index) and calibration curve showed that this model had moderate accuracy. The correlation analysis between the risk score and the infiltration of six common types of immune cells showed that the model could reflect the state of the immune microenvironment in HCC tumours.CONCLUSION:Our IRG prognostic model was shown to have value in the monitoring, treatment, and prognostic assessment of HCC patients and could be used as a survival prediction tool in the near future.
Prognostic Values of Immune Scores and Immune Microenvironment-Related Genes for Hepatocellular Carcinoma

Penglei Ge,Shifang Li,Chunbo Li,Yubin Fu,Zhengkai Feng,Lin Li,Gong Zhang,Zhiqiang Gao,Zhe Tang,Xiaowei Dang,Yang Wu

DOI: https://doi.org/10.2139/ssrn.3420394

2019-01-01

SSRN Electronic Journal

Abstract:Background: Immunotherapy, as a very promising treatment, has the potential to change the therapeutic landscape for malignancies. However, due to the complexity of immunotherapy and the heterogeneity of Hepatocellular carcinoma (HCC), it is crucial to grasp the characteristics of the tumour immune microenvironment to improve effects of immunotherapy. Methods: The ESTIMATE (Estimation of STromal and Immune cells in MAlignant Tumor tissues using Expression data) algorithm was used to calculate the immune and stromal scores for quantitative analysis of immune and stromal cell infiltration in HCC. The weighted gene co-expression network analysis (WGCNA) and protein-protein interaction (PPI) network were analysed to identify immune microenvironment-related genes. Findings: Immune and stromal scores calculated by ESTIMATE closely represented immune cell components in the tumour microenvironment. Patients with high immune scores had a higher 4-year survival rate. TP53, CTNNB1, and AXIN1 mutations significantly varied with immune scores. In immune score-related modules analysis, Kyoto encyclopaedia of genes and genomes (KEGG) pathways and gene ontology (GO) terms were closely related to immune processes, tumorigenesis, and metastasis. Twelve new immune microenvironment-related genes were identified and had significantly positive correlations with seven checkpoint genes. In prognostic analysis, eleven immune microenvironment-related genes exhibited high expression, nine of which were validated in the GSE62232 dataset and were significantly associated with a good prognosis (P<0.05). Interpretation: Calculating immune score and stromal score could help to determine tumour purity and immune cell infiltration in the tumour microenvironment. Nine immune microenvironment-related genes identified in this study had potential as prognostic markers for HCC. Funding Statement: This research received no external funding.Declaration of Interests: The authors have declared that no conflict of interest existsEthics Approval Statement: The data from TCGA, GEO and The Human Protein Atlas were all publicly available and open access, so no approval was needed from the ethics committees.
Development And Validation Of A Prognostic And Immunotherapeutically Relevant Model In Hepatocellular Carcinoma

Yu Wang,Yanting Xie,Junyong Ma,Yizhou Wang,Renyan Gong

DOI: https://doi.org/10.21037/atm-20-6112

IF: 3.616

2020-01-01

Annals of Translational Medicine

Abstract:Background: The tumor immune microenvironment is pivotal in predicting clinical outcomes and therapeutic efficacy in cancer patients. This study aims to develop an immune prediction model (IPM) to effectively predict prognosis and immunotherapeutic response in patients with hepatocellular carcinoma (HCC).Methods: An IPM was constructed and validated based on immune-related genes. The influence of IPM on the HCC immune microenvironment, as well as the possible mechanism, was comprehensively analyzed. The value of the model in predicting the response of HCC patients to immunotherapy was also evaluated.Results: A novel IPM based on eight genes was developed and validated to predict the prognosis of HCC patients. These genes are matrix metalloproteinase 12 (MMP12), heme oxygenise 1 (HMOX1), C-X-C motif chemokine receptor 6 (CXCR6), hepatoma-derived growth factor (HDGF), placental growth factor (PGF), tyrosine kinase 2 (TYK2), retinoid X receptor beta (RXRB), and cyclin-dependent kinase 4 (CDK4). High-risk patients showed significantly poorer survival than low-risk patients. A nomogram was also established based on the IPM and tumor, node, metastasis (TNM) classification, which showed some net clinical benefit. Gene set enrichment analysis (GSEA) revealed several significantly enriched oncological signatures and immunologic signatures. Furthermore, high-risk patients were characterized by severe clinicopathological characteristics and immune cell infiltration. Finally, we found the that the IPM showed a significant positive correlation with programmed cell death 1 (PDCD1), cluster of differentiation 274 (CD274), and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) expression, suggesting a potentially enhanced effects of immunotherapy antibodies in HCC patients with a high risk score.Conclusions: A novel IPM that could predict clinical prognosis and immunotherapeutic response in HCC patients was developed. Our findings not only provide new insights into the identification of HCC patients with poor survival, but also deepen our understanding of the immune microenvironment, as well as the mechanism of immunotherapy, in HCC.
Additional File 3 of Construction of a Predictive Model for Immunotherapy Efficacy in Lung Squamous Cell Carcinoma Based on the Degree of Tumor-Infiltrating Immune Cells and Molecular Typing

Lingge Yang,Shuli Wei,Jingnan Zhang,Qiongjie Hu,Wansong Hu,Mengqing Cao,Long Zhang,Yongfang Wang,Pingli Wang,Kai Wang

DOI: https://doi.org/10.6084/m9.figshare.20484975

2022-01-01

Abstract:Additional file 3: Table S2. The main clinical information of TCGA-LUSC, GSE126044, GSE135222 and our independent LUSC cohort.
Integrative Characterization of Immune-relevant Genes in Hepatocellular Carcinoma

Wei-Feng Hong,Yu-Jun Gu,Na Wang,Jie Xia,Heng-Yu Zhou,Ke Zhan,Ming-Xiang Cheng,Ying Cai

DOI: https://doi.org/10.14218/jcth.2020.00132

2021-03-08

Journal of Clinical and Translational Hepatology

Abstract:BACKGROUND AND AIMS: Tumor microenvironment plays an essential role in cancer development and progression. Cancer immunotherapy has become a promising approach for the treatment of hepatocellular carcinoma (HCC). We aimed to analyze the HCC immune microenvironment characteristics to identify immune-related genetic changes.METHODS: Key immune-relevant genes (KIRGs) were obtained through integrating the differentially expressed genes of The Cancer Genome Atlas, immune genes from the Immunology Database and Analysis Portal, and immune differentially expressed genes determined by single-sample gene set enrichment analysis scores. Cox regression analysis was performed to mine therapeutic target genes. A regulatory network based on KIRGs, transcription factors, and immune-related long non-coding RNAs (IRLncRNAs) was also generated. The outcomes of risk score model were validated in a testing cohort and in clinical samples using tissue immunohistochemistry staining. Correlation analysis between risk score and immune checkpoint genes and immune cell infiltration were investigated.RESULTS: In total, we identified 21 KIRGs, including programmed cell death-1 (PD-1) and cytotoxic T-lymphocyte associated protein 4 (CTLA4), and found IKBKE, IL2RG, EDNRA, and IGHA1 may be equally important to PD-1 or CTLA4. Meanwhile, KIRGs, various transcription factors, and IRLncRNAs were integrated to reveal that the NRF1-AC127024.5-IKBKE axis might be involved in tumor immunity regulation. Furthermore, the immune-related risk score model was established according to KIRGs and key IRLncRNAs, and verified more obvious discriminating power in the testing cohort. Correlation analysis indicated TNFSF4 , LGALS9 , KIAA1429 , IDO2, and CD276 were closely related to the risk score, and CD4 T cells, macrophages, and neutrophils were the primary immune infiltration cell types.CONCLUSIONS: Our results highlight the importance of immune genes in the HCC microenvironment and further unravel the underlying molecular mechanisms in the development of HCC.

gastroenterology & hepatology
Additional File 1 of Multi-omics Analysis Reveals Prognostic Value of Tumor Mutation Burden in Hepatocellular Carcinoma

Qianhui Xu,Hao Xu,Ruilong Deng,Zijie Wang,Nanjun Li,Zhixuan Qi,Jiaxin Zhao,Wen Huang

DOI: https://doi.org/10.6084/m9.figshare.14905897

2021-01-01

Abstract:Additional file 1. Supplementary Table S1: Clinical Characteristics of the HCC patients in TCGA and ICGC.Supplementary Table S2: TMB value of 365 HCC patients. Supplementary Table S3: The genes and corresponding modules after WGCNA. Supplementary Table S4: differentially expressed genes (DEGs) between low- and high-TMB groups. Supplementary Table S5: The Functional Annotation analysis of hub genes. Supplementary Table S6: The results of correlation of risk score with immune infiltrating cell.
Additional File 1 of Identification of a Tumor Microenvironment-Related Seven-Gene Signature for Predicting Prognosis in Bladder Cancer

Zhi Wang,Lei Tu,Minfeng Chen,Seo Yun Tong

DOI: https://doi.org/10.6084/m9.figshare.14767230

2021-01-01

Abstract:Additional file 1: Table S1. GO analysis of 4 TME-related co-expression modules (magenta, brown, purple and yellow).
Microenvironment Characterization and Multi-Omics Signatures Related to Prognosis and Immunotherapy Response of Hepatocellular Carcinoma

Furong Liu,Lu Qin,Zhibin Liao,Jia Song,Chaoyi Yuan,Yachong Liu,Yu Wang,Heze Xu,Qiaofeng Zhang,Youliang Pei,Hongwei Zhang,Yonglong Pan,Xiaoping Chen,Zhanguo Zhang,Wanguang Zhang,Bixiang Zhang

DOI: https://doi.org/10.1186/s40164-020-00165-3

2020-01-01

Abstract:Background Immune cell infiltration in the tumor microenvironment (TME) affects tumor initiation, patients’ prognosis and immunotherapy strategies. However, their roles and interactions with genomics and molecular processes in hepatocellular carcinoma (HCC) still have not been systematically evaluated. Methods We performed unsupervised clustering of total 1000 HCC samples including discovery and validation group from available public datasets. Immune heterogeneity of each subtype was explored by multi-dimension analysis. And a support vector machine (SVM) model based on multi-omics signatures was trained and tested. Finally, we performed immunohistochemistry to verify the immune role of signatures. Results We defined three immune subtypes in HCC, with diverse clinical, molecular, and genomic characteristics. Cluster1 had worse prognosis, better anti-tumor characteristics and highest immune scores, but also accompanied by immunosuppression and T cell dysfunction. Meanwhile, a better anti-PD1/CTLA4 immunotherapeutic response was predicted in cluster1. Cluster2 was enriched in TAM-M2 and stromal cells, indicating immunosuppression. Cluster3, with better prognosis, had lowest CD8 T cell but highest immune resting cells. Further, based on genomic signatures, we developed an SVM classifier to identify the patient’s immunological status, which was divided into Type A and Type B, in which Type A had poorer prognosis, higher T cell dysfunction despite higher T cell infiltration, and had better immunotherapeutic response. At the same time, MMP9 may be a potential predictor of the immune characteristics and immunotherapeutic response in HCC. Conclusions Our work demonstrated 3 immune clusters with different features. More importantly, multi-omics signatures, such as MMP9 was identified based on three clusters to help us recognize patients with different prognosis and responses to immunotherapy in HCC. This study could further reveal the immune status of HCC and provide potential predictors for immune checkpoint treatment response.
Identification of Prognostic Genes in the Tumor Microenvironment of Hepatocellular Carcinoma

Shixin Xiang,Jing Li,Jing Shen,Yueshui Zhao,Xu Wu,Mingxing Li,Xiao Yang,Parham Jabbarzadeh Kaboli,Fukuan Du,Yuan Zheng,Qinglian Wen,Chi Hin Cho,Tao Yi,Zhangang Xiao

DOI: https://doi.org/10.3389/fimmu.2021.653836

IF: 7.3

2021-04-07

Frontiers in Immunology

Abstract:Background: Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in the world. The efficacy of immunotherapy usually depends on the interaction of immunomodulation in the tumor microenvironment (TME). This study aimed to explore the potential stromal-immune score-based prognostic genes related to immunotherapy in HCC through bioinformatics analysis. Methods: ESTIMATE algorithm was applied to calculate the immune/stromal/Estimate scores and tumor purity of HCC using the Cancer Genome Atlas (TCGA) transcriptome data. Functional enrichment analysis of differentially expressed genes (DEGs) was analyzed by the Database for Annotation, Visualization, and Integrated Discovery database (DAVID). Univariate and multivariate Cox regression analysis and least absolute shrinkage and selection operator (LASSO) regression analysis were performed for prognostic gene screening. The expression and prognostic value of these genes were further verified by KM-plotter database and the Human Protein Atlas (HPA) database. The correlation of the selected genes and the immune cell infiltration were analyzed by single sample gene set enrichment analysis (ssGSEA) algorithm and Tumor Immune Estimation Resource (TIMER). Results: Data analysis revealed that higher immune/stromal/Estimate scores were significantly associated with better survival benefits in HCC within 7 years, while the tumor purity showed a reverse trend. DEGs based on both immune and stromal scores primarily affected the cytokine–cytokine receptor interaction signaling pathway. Among the DEGs, three genes (CASKIN1, EMR3, and GBP5) were found most significantly associated with survival. Moreover, the expression levels of CASKIN1, EMR3, and GBP5 genes were significantly correlated with immune/stromal/Estimate scores or tumor purity and multiple immune cell infiltration. Among them, GBP5 genes were highly related to immune infiltration. Conclusion: This study identified three key genes which were related to the TME and had prognostic significance in HCC, which may be promising markers for predicting immunotherapy outcomes.

immunology
An M6a-Related Prognostic Biomarker Associated with the Hepatocellular Carcinoma Immune Microenvironment

Yingxi Du,Yarui Ma,Qing Zhu,Tongzheng Liu,Yuchen Jiao,Peng Yuan,Xiaobing Wang

DOI: https://doi.org/10.3389/fphar.2021.707930

IF: 5.6

2021-01-01

Frontiers in Pharmacology

Abstract:Background: N6-methyladenosine (m6A) is related to the progression of multiple cancers. However, the underlying influences of m6A-associated genes on the tumor immune microenvironment in hepatocellular carcinoma (HCC) remain poorly understood. Therefore, we sought to construct a survival prediction model using m6A-associated genes to clarify the molecular and immune characteristics of HCC. Methods: HCC case data were downloaded from The Cancer Genome Atlas (TCGA). Then, by applying consensus clustering, we identified two distinct HCC clusters. Next, four m6A-related genes were identified to construct a prognostic model, which we validated with Gene Expression Omnibus (GEO) and International Cancer Genome Consortium (ICGC) datasets. Additionally, the molecular and immune characteristics in different subgroups were analyzed. Results: m6A RNA methylation regulators were differentially expressed between HCC and normal samples and linked with immune checkpoint expression. Using consensus clustering, we divided HCC samples into two subtypes with distinct clinical features. Cluster 2 was associated with unfavorable prognosis, higher immune checkpoint expression and immune cell infiltration levels. In addition, the immune and carcinogenic signaling pathways were enriched in cluster 2. Furthermore, we constructed a risk model using four m6A-associated genes. Patients with different risk scores had distinct survival times, expression levels of immunotherapy biomarkers, TP53 mutation rates, and sensitivities to chemotherapy and targeted therapy. Similarly, the model exhibited an identical impact on overall survival in the validation cohorts. Conclusion: The constructed m6A-based signature may be promising as a biomarker for prognostics and to distinguish immune characteristics in HCC.
Additional File 5 of Diagnostic and Prognostic Values of Pyroptosis-Related Genes for the Hepatocellular Carcinoma

Mindan Xing,Jia Li

DOI: https://doi.org/10.6084/m9.figshare.19766420

2022-01-01

Abstract:Additional file 5. The gene set associated with the immune-related pathways.
Development of Prognostic Model Based on Five-gene Related to Tumor Mutation Burden in Hepatocellular Carcinoma

Zhou Shujun,Qingling Li,Bin Yu,Qifa Ye,Yanfeng Wang

DOI: https://doi.org/10.21203/rs.3.rs-1010581/v1

2021-01-01

Abstract:BackgroundHepatocellular carcinoma (HCC) , the incidence rate ranks sixth and regards as the second leading cause of cancer-related death in the world. Tumor mutation burden (TMB) , a novel biomarker featured with microsatellite instability, has been thought to be closely related to tumor microenvironment and immunotherapy.MethodsIn this study, the 357 HCC samples were download from The Cancer Genome Atlas (TCGA) and analyzed.ResultsSingle nucleotide polymorphism (SNP) and C > T variation had the most missense mutations, and we also observed the higher mutation frequency in TP53, TTN, CTNNB1. With an optimal cut-off value of 4.61, the high level of TMB presented a worse prognosis. Functional analysis of the differentially expressed genes (DEGs) showed they were enriched in the pathway of the formation of extracellular matrix organization and sulfur compound metabolic. A 5-gene-based (including SFRP4, IL7R, FBLN2, COLEC10 and CHGA) model has been constructed to explore the independent prognosis capacity of each HCC patient.ConclusionsThe establishment of 5-gene-based prognosis model functions well in predicting the median of 1- , 3- and 5-year outcome of the individual patient and which will be beneficial for pre-clinical diagnosis and therapeutic decision-making.
Identification, Verification and Pathway Enrichment Analysis of Prognosis-Related Immune Genes in Patients With Hepatocellular Carcinoma

Zhipeng Zhu,Mengyu Song,Wenhao Li,Mengying Li,Sihan Chen,Bo Chen

DOI: https://doi.org/10.3389/fonc.2021.695001

IF: 4.7

2021-09-20

Frontiers in Oncology

Abstract:Hepatocellular carcinoma is a common malignant tumor with poor prognosis, poor treatment effect, and lack of effective biomarkers. In this study, bioinformatics analysis of immune-related genes of hepatocellular carcinoma was used to construct a multi-gene combined marker that can predict the prognosis of patients. The RNA expression data of hepatocellular carcinoma were downloaded from The Cancer Genome Atlas (TCGA) database, and immune-related genes were obtained from the IMMPORT database. Differential analysis was performed by Wilcox test to obtain differentially expressed genes. Univariate Cox regression analysis, lasso regression analysis and multivariate Cox regression analysis were performed to establish a prognostic model of immune genes, a total of 5 genes ( HDAC1, BIRC5, SPP1, STC2, NR6A1 ) were identified to construct the models. The expression levels of 5 genes in HCC tissues were significantly different from those in paracancerous tissues. The Kaplan-Meier survival curve showed that the risk score calculated according to the prognostic model was significantly related to the overall survival (OS) of HCC. The receiver operating characteristic (ROC) curve confirmed that the prognostic model had high accuracy. Independent prognostic analysis was performed to prove that the risk value can be used as an independent prognostic factor. Then, the gene expression data of hepatocellular carcinoma in the ICGC database was used as a validation data set for the verification of the above steps. In addition, we used the CIBERSORT software and TIMER database to conduct immune infiltration research, and the results showed that the five genes of the model and the risk score have a certain correlation with the content of immune cells. Moreover, through Gene Set Enrichment Analysis (GSEA) and the construction of protein interaction networks, we found that the p53-mediated signal transduction pathway is a potentially important signal pathway for hepatocellular carcinoma and is positively regulated by certain genes in the prognostic model. In conclusion, this study provides potential targets for predicting the prognosis and treatment of hepatocellular carcinoma patients, and also provides new ideas about the correlation between immune genes and potential pathways of hepatocellular carcinoma.

oncology

Additional File 6 of Model Based on Five Tumour Immune Microenvironment-Related Genes for Predicting Hepatocellular Carcinoma Immunotherapy Outcomes

Based on Tumor Mutation Burden to construct diagnosis and prognosis models and provides guidance for the treatment in the Hepatocellular Carcinoma patients

Diagnosis and prognosis models for hepatocellular carcinoma patient's management based on tumor mutation burden

Model based on five tumour immune microenvironment-related genes for predicting hepatocellular carcinoma immunotherapy outcomes

Comprehensive Study of Tumor Immune Microenvironment and Relevant Genes in Hepatocellular Carcinoma Identifies Potential Prognostic Significance

Immune Classifier-Based Signatures Provide Good Prognostic Stratification and Predict the Clinical Benefits of Immune-Based Therapies for Hepatocellular Carcinoma

Systematic Construction and Validation of a Prognostic Model for Hepatocellular Carcinoma Based on Immune-Related Genes

Identification and validation of immune-related gene signature models for predicting prognosis and immunotherapy response in hepatocellular carcinoma

A Prognostic Model Based on Seven Immune-Related Genes Predicts the Overall Survival of Patients with Hepatocellular Carcinoma

Prognostic Values of Immune Scores and Immune Microenvironment-Related Genes for Hepatocellular Carcinoma

Development And Validation Of A Prognostic And Immunotherapeutically Relevant Model In Hepatocellular Carcinoma

Additional File 3 of Construction of a Predictive Model for Immunotherapy Efficacy in Lung Squamous Cell Carcinoma Based on the Degree of Tumor-Infiltrating Immune Cells and Molecular Typing

Integrative Characterization of Immune-relevant Genes in Hepatocellular Carcinoma

Additional File 1 of Multi-omics Analysis Reveals Prognostic Value of Tumor Mutation Burden in Hepatocellular Carcinoma

Additional File 1 of Identification of a Tumor Microenvironment-Related Seven-Gene Signature for Predicting Prognosis in Bladder Cancer

Microenvironment Characterization and Multi-Omics Signatures Related to Prognosis and Immunotherapy Response of Hepatocellular Carcinoma

Identification of Prognostic Genes in the Tumor Microenvironment of Hepatocellular Carcinoma

An M6a-Related Prognostic Biomarker Associated with the Hepatocellular Carcinoma Immune Microenvironment

Additional File 5 of Diagnostic and Prognostic Values of Pyroptosis-Related Genes for the Hepatocellular Carcinoma

Development of Prognostic Model Based on Five-gene Related to Tumor Mutation Burden in Hepatocellular Carcinoma

Identification, Verification and Pathway Enrichment Analysis of Prognosis-Related Immune Genes in Patients With Hepatocellular Carcinoma